JP7581385B2 - 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 - Google Patents
経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 Download PDFInfo
- Publication number
- JP7581385B2 JP7581385B2 JP2022577750A JP2022577750A JP7581385B2 JP 7581385 B2 JP7581385 B2 JP 7581385B2 JP 2022577750 A JP2022577750 A JP 2022577750A JP 2022577750 A JP2022577750 A JP 2022577750A JP 7581385 B2 JP7581385 B2 JP 7581385B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- peptide
- compound
- substituent
- absent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024187587A JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055026P | 2020-07-22 | 2020-07-22 | |
| US63/055,026 | 2020-07-22 | ||
| EP20192414 | 2020-08-24 | ||
| EP20192414.9 | 2020-08-24 | ||
| US202163156988P | 2021-03-05 | 2021-03-05 | |
| US63/156,988 | 2021-03-05 | ||
| PCT/EP2021/070485 WO2022018186A1 (en) | 2020-07-22 | 2021-07-22 | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187587A Division JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534131A JP2023534131A (ja) | 2023-08-08 |
| JPWO2022018186A5 JPWO2022018186A5 (enExample) | 2024-07-24 |
| JP7581385B2 true JP7581385B2 (ja) | 2024-11-12 |
Family
ID=77179985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577750A Active JP7581385B2 (ja) | 2020-07-22 | 2021-07-22 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
| JP2024187587A Pending JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187587A Pending JP2025020197A (ja) | 2020-07-22 | 2024-10-24 | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220177538A1 (enExample) |
| EP (1) | EP4185607A1 (enExample) |
| JP (2) | JP7581385B2 (enExample) |
| KR (2) | KR102446310B1 (enExample) |
| CN (1) | CN116157143A (enExample) |
| AU (1) | AU2021312323A1 (enExample) |
| BR (1) | BR112023000270A2 (enExample) |
| CA (1) | CA3184717A1 (enExample) |
| CL (1) | CL2023000087A1 (enExample) |
| CO (1) | CO2023000097A2 (enExample) |
| IL (1) | IL299701A (enExample) |
| MX (1) | MX2023000303A (enExample) |
| PE (1) | PE20231841A1 (enExample) |
| TW (2) | TW202315883A (enExample) |
| WO (1) | WO2022018186A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) * | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| JP2025523681A (ja) * | 2022-07-13 | 2025-07-23 | 杭州中美華東製薬有限公司 | Ｇｌｐ－１／ｇｉｐ二重アゴニスト、その調製方法および使用 |
| WO2024110614A1 (en) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| TW202529796A (zh) * | 2023-11-22 | 2025-08-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1r/gipr雙標靶激動劑在製備動物藥的用途 |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025133045A1 (en) | 2023-12-22 | 2025-06-26 | Novo Nordisk A/S | Fermentation process |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025176999A2 (en) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Novel compounds |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| RU2578591C2 (ru) | 2008-12-19 | 2016-03-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Лекарственные средства, связанные с дипептидами |
| AR074811A1 (es) | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| HUE027229T2 (en) | 2009-12-16 | 2016-08-29 | Novo Nordisk As | Double acylated glp-1 derivatives |
| CA2796894A1 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| EP2588127A4 (en) | 2010-06-24 | 2014-06-11 | Univ Indiana Res & Tech Corp | DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES |
| HRP20180425T1 (hr) | 2010-12-16 | 2018-04-20 | Novo Nordisk A/S | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline |
| US8975223B2 (en) * | 2010-12-22 | 2015-03-10 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146 |
| WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| JP5914641B2 (ja) | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
| WO2013139695A1 (en) * | 2012-03-22 | 2013-09-26 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| IN2014MN02304A (enExample) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| PL2864350T3 (pl) | 2012-06-21 | 2019-01-31 | Indiana University Research And Technology Corporation | Analogi glukagonu wykazujące aktywność wobec receptora GIP |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| US20160058881A1 (en) | 2013-03-15 | 2016-03-03 | Indiana University Research And Technology Corporation | Prodrugs with prolonged action |
| ES2688462T3 (es) * | 2013-05-02 | 2018-11-02 | Novo Nordisk A/S | Dosificación oral de compuestos de GLP-1 |
| WO2014192284A1 (en) | 2013-05-28 | 2014-12-04 | Takeda Pharmaceutical Company Limited | Peptide compound |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| WO2015035419A1 (en) | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| CN105849122B (zh) * | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| JP6701208B2 (ja) | 2014-09-24 | 2020-05-27 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 脂質化アミド系インスリンプロドラッグ |
| WO2016077220A1 (en) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| US10501516B2 (en) | 2016-05-24 | 2019-12-10 | Takeda Pharmaceutical Company Limited | Peptide compound |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| AU2019263674B2 (en) | 2018-05-04 | 2023-03-02 | Novo Nordisk A/S | GIP derivatives and uses thereof |
| CN112469431A (zh) | 2018-07-23 | 2021-03-09 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| UA128697C2 (uk) | 2018-07-23 | 2024-10-02 | Елі Ліллі Енд Компані | Способи застосування коагоніста gip/glp-1 для терапії |
| TW202523681A (zh) | 2018-07-23 | 2025-06-16 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| CN110642935A (zh) | 2019-09-25 | 2020-01-03 | 成都奥达生物科技有限公司 | 一种替瑞帕肽类似物 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
-
2021
- 2021-07-22 BR BR112023000270A patent/BR112023000270A2/pt unknown
- 2021-07-22 IL IL299701A patent/IL299701A/en unknown
- 2021-07-22 CA CA3184717A patent/CA3184717A1/en active Pending
- 2021-07-22 JP JP2022577750A patent/JP7581385B2/ja active Active
- 2021-07-22 TW TW111150185A patent/TW202315883A/zh unknown
- 2021-07-22 KR KR1020217034294A patent/KR102446310B1/ko active Active
- 2021-07-22 MX MX2023000303A patent/MX2023000303A/es unknown
- 2021-07-22 US US17/383,192 patent/US20220177538A1/en not_active Abandoned
- 2021-07-22 AU AU2021312323A patent/AU2021312323A1/en active Pending
- 2021-07-22 US US18/017,041 patent/US20230272029A1/en active Pending
- 2021-07-22 TW TW110126883A patent/TWI801942B/zh active
- 2021-07-22 CN CN202180059832.9A patent/CN116157143A/zh active Pending
- 2021-07-22 KR KR1020217034342A patent/KR20230029480A/ko not_active Ceased
- 2021-07-22 PE PE2023000026A patent/PE20231841A1/es unknown
- 2021-07-22 EP EP21749558.9A patent/EP4185607A1/en active Pending
- 2021-07-22 WO PCT/EP2021/070485 patent/WO2022018186A1/en not_active Ceased
-
2022
- 2022-01-12 US US17/574,079 patent/US11779648B2/en active Active
- 2022-11-04 US US17/980,990 patent/US20230120597A1/en not_active Abandoned
-
2023
- 2023-01-05 CO CONC2023/0000097A patent/CO2023000097A2/es unknown
- 2023-01-09 CL CL2023000087A patent/CL2023000087A1/es unknown
-
2024
- 2024-10-24 JP JP2024187587A patent/JP2025020197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021312323A1 (en) | 2023-02-02 |
| CA3184717A1 (en) | 2022-01-27 |
| US11779648B2 (en) | 2023-10-10 |
| US20230272029A1 (en) | 2023-08-31 |
| TWI801942B (zh) | 2023-05-11 |
| MX2023000303A (es) | 2023-02-09 |
| CL2023000087A1 (es) | 2023-07-07 |
| BR112023000270A2 (pt) | 2023-01-31 |
| JP2025020197A (ja) | 2025-02-12 |
| TW202208411A (zh) | 2022-03-01 |
| TW202315883A (zh) | 2023-04-16 |
| CO2023000097A2 (es) | 2023-03-27 |
| US20230120597A1 (en) | 2023-04-20 |
| US20220177538A1 (en) | 2022-06-09 |
| EP4185607A1 (en) | 2023-05-31 |
| KR102446310B1 (ko) | 2022-09-23 |
| US20220125940A1 (en) | 2022-04-28 |
| CN116157143A (zh) | 2023-05-23 |
| JP2023534131A (ja) | 2023-08-08 |
| IL299701A (en) | 2023-03-01 |
| KR20230029480A (ko) | 2023-03-03 |
| KR20220012840A (ko) | 2022-02-04 |
| PE20231841A1 (es) | 2023-11-21 |
| WO2022018186A1 (en) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7581385B2 (ja) | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 | |
| TWI707865B (zh) | Gip衍生物及其用途 | |
| US20230391845A1 (en) | Glp-1, gip and glucagon receptor triple agonists | |
| US20230346961A1 (en) | Glp-1 and gip receptor co-agonists | |
| JP7434616B2 (ja) | プロドラッグおよびその使用 | |
| EA049130B1 (ru) | Коагонисты рецепторов glp-1 и gip, подходящие для пероральной доставки | |
| CN118632867A (zh) | Glp-1/gip受体共激动剂前药及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230220 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230227 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230417 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240712 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240712 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240712 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240930 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241030 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7581385 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |